- Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsEli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…BioSpace · 7d ago↗ source
- STAT+: The next step of site-neutral, and a fiery PBM hearingMedicare proposes to reduce payments to hospitals for certain drugs and imaging services.STAT · 7d ago↗ source
- FDA’s radical transparency policy for rejections runs into legal uncertaintyHaving started to publish CRLs without consulting the public, the FDA is under pressure to change course amid concerns it failed to openly and fully evaluate a complex issue.